



Press release – March 17, 2008

VÉTOQUINOL S.A. AND JUROX PTY LTD EXTEND THEIR COLLABORATION ON ALFAXAN® IN EUROPE

RUTHERFORD (Australia) and LURE (France), March 17- Australian veterinary pharmaceuticals manufacturer Jurox Pty. Ltd. and French veterinary pharmaceutical laboratory Vétoquinol have confirmed that the European launch of Alfaxan®, an injectable anaesthetic used for the induction and maintenance of anaesthesia in cats and dogs will proceed in the next few months.

“The mutual recognition process (MRP) and subsequent registration of Alfaxan® in France, Germany, Spain, Netherlands, Belgium and Ireland is completed and we expect marketing authorization in those countries very soon” according to Matthieu Frechin, Group Director – Strategy and Development at Vétoquinol. “Alfaxan® is a perfect fit in our focused strategy on the segment of pain and inflammation management that includes anaesthesia.”

As part of the preparations for the roll out of the product in the next few months, Jurox Head of Research and Development Dr. Ted Whittem has just completed a round of meetings with key Vetoquinol staff and presented technical information to veterinarians who are key opinion leaders on Alfaxan® at the Vétoquinol Academia recently held in Brussels (Belgium). That event brought together 150 veterinarians specialists in surgery and anaesthesia from all over Europe.

During his presentation Dr Whittem commented that “due to the unique chemistry involved in the delivery system of the active ingredient alfaxalone, induction of anaesthesia with Alfaxan® is controlled and safe due to the wide margin of safety of the product, while recoveries are smooth and fast, making Alfaxan® the ideal anaesthetic in most conditions.”

Jurox Head of Sales and Marketing Tony Cooley said that 14 months after Vetoquinol’s extremely successful launch of Alfaxan® in the United Kingdom, continental Europe was the next logical step in the collaboration on Alfaxan® for both organizations.

.../...

About Jurox

Jurox based at Rutherford in The Hunter Valley is a family-owned veterinary pharmaceutical company that markets in excess of 120 proprietary animal health products and employs over 90 staff in Australia and New Zealand. The group invests 12% of sales in research and development, much of which is carried out on the Group's own research stations. With an expanding export base and growing domestic business, Jurox now markets products throughout Australia, New Zealand, Asia and The Middle East and is now turning its attention to Europe and North America. The Jurox manufacturing facility is ISO9001, GMP, GLP and NATA accredited. For further details contact Jurox at www.jurox.com or +61 2 4931 8200.

About Vétoquinol

Vétoquinol, established in 1933, is an independent veterinary pharmaceutical laboratory for both food producing animals and pets. This family-owned Group, dedicated to animal health, is the world's 12th largest laboratory in its field. Nearly 80% of its revenue is now generated in export markets. Its business includes research, production and marketing of drugs and health products. Vétoquinol, positioned in the treatment field, has extensive expertise in 3 major therapeutic fields: anti-infection agents, pain and inflammatory, and cardiology-nephrology. The Group now distributes its products in about one hundred countries (Europe, North America and Asia), working through 18 subsidiaries and a network of 110 distributor-partners. The company had more than 1,300 employees worldwide.

Upcoming events: 2007 Annual results (Tuesday, 18 March 2008)

More information: www.vetoquinol.com

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For further information, contact

VETOQUINOL
Finance Department
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION
Investor Relations
Emmanuel DOVERGNE
Tel.: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr

Media Relations
Alix HÉRIARD DUBREUIL
Tel.: +33 (0)1 56 43 44 62
alix.heriard@keima.fr